Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Oct;33(10):1655–1661. doi: 10.1128/aac.33.10.1655

Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

J S Wolfson 1, D C Hooper 1
PMCID: PMC172733  PMID: 2686545

Full text

PDF
1655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adhami Z. N., Wise R., Weston D., Crump B. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother. 1984 Jan;13(1):87–92. doi: 10.1093/jac/13.1.87. [DOI] [PubMed] [Google Scholar]
  2. Allais J. M., Preheim L. C., Cuevas T. A., Roccaforte J. S., Mellencamp M. A., Bittner M. J. Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections. Antimicrob Agents Chemother. 1988 Sep;32(9):1327–1330. doi: 10.1128/aac.32.9.1327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arrigo G., Cavaliere G., D'Amico G., Passarella E., Broccali G. Pharmacokinetics of norfloxacin in chronic renal failure. Int J Clin Pharmacol Ther Toxicol. 1985 Sep;23(9):491–496. [PubMed] [Google Scholar]
  4. Barre J., Houin G., Tillement J. P. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci. 1984 Oct;73(10):1379–1382. doi: 10.1002/jps.2600731014. [DOI] [PubMed] [Google Scholar]
  5. Block J. M., Walstad R. A., Bjertnaes A., Hafstad P. E., Holte M., Ottemo I., Svarva P. L., Rolstad T., Peterson L. E. Ofloxacin versus trimethoprim-sulphamethoxazole in acute cystitis. Drugs. 1987;34 (Suppl 1):100–106. doi: 10.2165/00003495-198700341-00022. [DOI] [PubMed] [Google Scholar]
  6. Bologna M., Vaggi L., Flammini D., Carlucci G., Forchetti C. M. Norfloxacin in prostatitis: correlation between HPLC tissue concentrations and clinical results. Drugs Exp Clin Res. 1985;11(2):95–100. [PubMed] [Google Scholar]
  7. Brown E. M., Morris R., Stephenson T. P. The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):123–127. doi: 10.1093/jac/18.supplement_d.123. [DOI] [PubMed] [Google Scholar]
  8. Campoli-Richards D. M., Monk J. P., Price A., Benfield P., Todd P. A., Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373–447. doi: 10.2165/00003495-198835040-00003. [DOI] [PubMed] [Google Scholar]
  9. Cherubin C., Stilwell S. Norfloxacin versus parenteral therapy in the treatment of complicated urinary tract infections and resistant organisms. Scand J Infect Dis Suppl. 1986;48:32–37. [PubMed] [Google Scholar]
  10. Corrado M. L., Grad C., Sabbaj J. Norfloxacin in the treatment of urinary tract infections in men with and without identifiable urologic complications. Am J Med. 1987 Jun 26;82(6B):70–74. doi: 10.1016/0002-9343(87)90622-x. [DOI] [PubMed] [Google Scholar]
  11. Cox C. E. A comparison of enoxacin and co-trimoxazole in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother. 1988 Feb;21 (Suppl B):113–118. doi: 10.1093/jac/21.suppl_b.113. [DOI] [PubMed] [Google Scholar]
  12. Cox C. E., Callery S. V., Tack K. J. Clinical experience with ofloxacin in urinary tract infection. Infection. 1986;14 (Suppl 4):S303–S304. doi: 10.1007/BF01661300. [DOI] [PubMed] [Google Scholar]
  13. Cox C. E., McCabe R. E., Grad C. Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection. Am J Med. 1987 Jun 26;82(6B):59–64. doi: 10.1016/0002-9343(87)90620-6. [DOI] [PubMed] [Google Scholar]
  14. Daikos G. L., Kathpalia S. B., Sharifi R., Lolans V. T., Jackson G. G. Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. Am J Med. 1987 Apr 27;82(4A):290–294. [PubMed] [Google Scholar]
  15. Desplaces N., Gutmann L., Carlet J., Guibert J., Acar J. F. The new quinolones and their combinations with other agents for therapy of severe infections. J Antimicrob Chemother. 1986 Mar;17 (Suppl A):25–39. doi: 10.1093/jac/17.suppl_a.25. [DOI] [PubMed] [Google Scholar]
  16. Drew R. H., Gallis H. A. Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application. Pharmacotherapy. 1988;8(1):35–46. doi: 10.1002/j.1875-9114.1988.tb04063.x. [DOI] [PubMed] [Google Scholar]
  17. Edlund C., Nord C. E. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora. Infection. 1988;16(1):8–12. doi: 10.1007/BF01646921. [DOI] [PubMed] [Google Scholar]
  18. Garlando F., Rietiker S., Täuber M. G., Flepp M., Meier B., Lüthy R. Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother. 1987 Feb;31(2):354–356. doi: 10.1128/aac.31.2.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Giamarellou H., Tsagarakis J., Petrikkos G., Daikos G. K. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):266–269. doi: 10.1007/BF02029530. [DOI] [PubMed] [Google Scholar]
  20. Goldstein E. J., Alpert M. L., Ginsberg B. P. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. Antimicrob Agents Chemother. 1985 Mar;27(3):422–423. doi: 10.1128/aac.27.3.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Goldstein E. J., Alpert M. L., Najem A., Eng R. H., Ginsburg B. P., Kahn R. M., Cherubin C. E. Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial. Am J Med. 1987 Jun 26;82(6B):65–69. doi: 10.1016/0002-9343(87)90621-8. [DOI] [PubMed] [Google Scholar]
  22. Guerra J. G., Falconi E., Palomino J. C., Benavente L., Antunez de Mayolo E. Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):260–265. doi: 10.1007/BF02029529. [DOI] [PubMed] [Google Scholar]
  23. Guibert J. M., Destree D. M., Acar J. F. Ciprofloxacin (BAY 09867): clinical evaluation in urinary tract infections due to Pseudomonas aeruginosa. Chemioterapia. 1987 Jun;6(2 Suppl):524–525. [PubMed] [Google Scholar]
  24. Guibert J., Acar J. F. Ofloxacine (RU 43280): évaluation clinique dans les infections urinaires et prostatiques. Pathol Biol (Paris) 1986 May;34(5):494–497. [PubMed] [Google Scholar]
  25. Haase D. A., Harding G. K., Thomson M. J., Kennedy J. K., Urias B. A., Ronald A. R. Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora. Antimicrob Agents Chemother. 1984 Oct;26(4):481–484. doi: 10.1128/aac.26.4.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Henry N. K., Schultz H. J., Grubbs N. C., Muller S. M., Ilstrup D. M., Wilson W. R. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):103–106. doi: 10.1093/jac/18.supplement_d.103. [DOI] [PubMed] [Google Scholar]
  27. Holmes B., Brogden R. N., Richards D. M. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Dec;30(6):482–513. doi: 10.2165/00003495-198530060-00003. [DOI] [PubMed] [Google Scholar]
  28. Hooper D. C., Wolfson J. S. Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrob Agents Chemother. 1989 Oct;33(10):1662–1667. doi: 10.1128/aac.33.10.1662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hächler H., Vogt K., Binswanger U., von Graevenitz A. Centrifugation of 50 ml of peritoneal fluid is sufficient for microbiological examination in continuous ambulatory peritoneal dialysis (CAPD) patients with peritonitis. Infection. 1986 May-Jun;14(3):102–104. doi: 10.1007/BF01643471. [DOI] [PubMed] [Google Scholar]
  30. Kishi H., Nito H., Saito I., Nishimura Y., Niijima T., Ohmori H., Tanaka H., Fujita Y., Deguchi K., Ogawa N. [Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method]. Hinyokika Kiyo. 1984 Sep;30(9):1307–1355. [PubMed] [Google Scholar]
  31. Kosmidis J., Gargalianos P., Adamis G., Petropoulou D., Makris D. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):219–221. doi: 10.1093/jac/22.supplement_d.219. [DOI] [PubMed] [Google Scholar]
  32. Kromann-Andersen B., Sommer P., Pers C., Larsen V., Rasmussen F. Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):143–147. doi: 10.1093/jac/22.supplement_c.143. [DOI] [PubMed] [Google Scholar]
  33. LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy. 1988;8(1):3–33. doi: 10.1002/j.1875-9114.1988.tb04058.x. [DOI] [PubMed] [Google Scholar]
  34. Leigh D. A., Emmanuel F. X., Petch V. J. Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):117–121. doi: 10.1093/jac/18.supplement_d.117. [DOI] [PubMed] [Google Scholar]
  35. Leigh D. A., Emmanuel F. X. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin. J Antimicrob Chemother. 1984 May;13 (Suppl B):85–88. doi: 10.1093/jac/13.suppl_b.85. [DOI] [PubMed] [Google Scholar]
  36. Leigh D. A., Smith E. C., Marriner J. Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients. J Antimicrob Chemother. 1984 May;13 (Suppl B):79–83. doi: 10.1093/jac/13.suppl_b.79. [DOI] [PubMed] [Google Scholar]
  37. Ludwig G., Pauthner H. Clinical experience with ofloxacin in upper and lower urinary tract infections. A comparison with co-trimoxazole and nitrofurantoin. Drugs. 1987;34 (Suppl 1):95–99. doi: 10.2165/00003495-198700341-00021. [DOI] [PubMed] [Google Scholar]
  38. Malinverni R., Glauser M. P. Comparative studies of fluoroquinolones in the treatment of urinary tract infections. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S153–S163. doi: 10.1093/clinids/10.supplement_1.s153. [DOI] [PubMed] [Google Scholar]
  39. Monk J. P., Campoli-Richards D. M. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987 Apr;33(4):346–391. doi: 10.2165/00003495-198733040-00003. [DOI] [PubMed] [Google Scholar]
  40. Møller B. R., Kaspersen P., Mamsen A., Korsager B., Quitzau K. Fleroxacin in the treatment of uncomplicated acute cystitis in women. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):215–218. doi: 10.1093/jac/22.supplement_d.215. [DOI] [PubMed] [Google Scholar]
  41. Neu H. C. Clinical use of the quinolones. Lancet. 1987 Dec 5;2(8571):1319–1322. doi: 10.1016/s0140-6736(87)91205-0. [DOI] [PubMed] [Google Scholar]
  42. Newsom S. W., Murphy P., Matthews J. A comparative study of ciprofloxacin and trimethoprim in the treatment of urinary tract infections in geriatric patients. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):111–115. doi: 10.1093/jac/18.supplement_d.111. [DOI] [PubMed] [Google Scholar]
  43. Nix D. E., Schentag J. J. The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 1988 Feb;28(2):169–178. doi: 10.1002/j.1552-4604.1988.tb05740.x. [DOI] [PubMed] [Google Scholar]
  44. Nix D. E., Schultz R. W., Frost R. W., Sedman A. J., Thomas D. J., Kinkel A. W., Schentag J. J. The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. J Antimicrob Chemother. 1988 Feb;21 (Suppl B):87–95. doi: 10.1093/jac/21.suppl_b.87. [DOI] [PubMed] [Google Scholar]
  45. Ode B., Walder M., Forsgren A. Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females. Scand J Infect Dis. 1987;19(6):677–679. doi: 10.3109/00365548709117203. [DOI] [PubMed] [Google Scholar]
  46. Panneton A. C., Bergeron M. G., LeBel M. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. Antimicrob Agents Chemother. 1988 Oct;32(10):1515–1520. doi: 10.1128/aac.32.10.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Peters H. J. Comparison of intravenous ciprofloxacin and mezlocillin in treatment of complicated urinary tract infection. Eur J Clin Microbiol. 1986 Apr;5(2):253–255. doi: 10.1007/BF02014003. [DOI] [PubMed] [Google Scholar]
  48. Preheim L. C., Cuevas T. A., Roccaforte J. S., Mellencamp M. A., Bittner M. J. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. Am J Med. 1987 Apr 27;82(4A):295–300. [PubMed] [Google Scholar]
  49. Reeves D. S., Lacey R. W., Mummery R. V., Mahendra M., Bint A. J., Newsom S. W. Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study. J Antimicrob Chemother. 1984 May;13 (Suppl B):99–105. doi: 10.1093/jac/13.suppl_b.99. [DOI] [PubMed] [Google Scholar]
  50. Rugendorff E. W. Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections. Drugs. 1987;34 (Suppl 1):91–94. doi: 10.2165/00003495-198700341-00020. [DOI] [PubMed] [Google Scholar]
  51. Saavedra S., Ramírez-Ronda C. H., Nevárez M. Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria. Eur J Clin Microbiol. 1986 Apr;5(2):255–257. doi: 10.1007/BF02014004. [DOI] [PubMed] [Google Scholar]
  52. Sabbaj J., Hoagland V. L., Cook T. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. Scand J Infect Dis Suppl. 1986;48:48–53. [PubMed] [Google Scholar]
  53. Sabbaj J., Hoagland V. L., Shih W. J. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother. 1985 Mar;27(3):297–301. doi: 10.1128/aac.27.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Sanders W. E., Jr Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis. 1988 May-Jun;10(3):528–543. doi: 10.1093/clinids/10.3.528. [DOI] [PubMed] [Google Scholar]
  55. Schaeffer A. J., Sisney G. A. Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora. J Urol. 1985 Apr;133(4):628–630. doi: 10.1016/s0022-5347(17)49118-x. [DOI] [PubMed] [Google Scholar]
  56. Sheehan G. J., Harding G. K., Haase D. A., Thomson M. J., Urias B., Kennedy J. K., Hoban D. J., Ronald A. R. Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection. Antimicrob Agents Chemother. 1988 Aug;32(8):1292–1293. doi: 10.1128/aac.32.8.1292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Stamm W. E., Hooton T. M., Johnson J. R., Johnson C., Stapleton A., Roberts P. L., Moseley S. L., Fihn S. D. Urinary tract infections: from pathogenesis to treatment. J Infect Dis. 1989 Mar;159(3):400–406. doi: 10.1093/infdis/159.3.400. [DOI] [PubMed] [Google Scholar]
  58. Stein G. E., Mummaw N., Goldstein E. J., Boyko E. J., Reller L. B., Kurtz T. O., Miller K., Cox C. E. A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections. Arch Intern Med. 1987 Oct;147(10):1760–1762. [PubMed] [Google Scholar]
  59. Stein G. E. Review of the bioavailability and pharmacokinetics of oral norfloxacin. Am J Med. 1987 Jun 26;82(6B):18–21. doi: 10.1016/0002-9343(87)90613-9. [DOI] [PubMed] [Google Scholar]
  60. Suzuki K., Tamai H., Naide Y., Ando K., Moriguchi R. [Laboratory and clinical study of ofloxacin in the treatment of bacterial prostatitis]. Hinyokika Kiyo. 1984 Oct;30(10):1505–1518. [PubMed] [Google Scholar]
  61. Tartaglione T. A., Johnson C. R., Brust P., Opheim K., Hooton T. M., Stamm W. E. Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis. Antimicrob Agents Chemother. 1988 Nov;32(11):1640–1643. doi: 10.1128/aac.32.11.1640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Vogel R., Deaney N. B., Round E. M., VandenBurg M. J., Currie W. J. Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections. J Antimicrob Chemother. 1984 May;13 (Suppl B):113–120. doi: 10.1093/jac/13.suppl_b.113. [DOI] [PubMed] [Google Scholar]
  63. Vogt P., Schorn T., Frei U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipients. Infection. 1988 May-Jun;16(3):175–178. doi: 10.1007/BF01644096. [DOI] [PubMed] [Google Scholar]
  64. Watt B., Chait I., Kelsey M. C., Newsom S. W., Newsom R. A., Smith J., Toase P. D., Deaney N. B., Round E. M., Vogel R. Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial. J Antimicrob Chemother. 1984 May;13 (Suppl B):89–94. doi: 10.1093/jac/13.suppl_b.89. [DOI] [PubMed] [Google Scholar]
  65. Weidner W., Schiefer H. G., Dalhoff A. Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. Am J Med. 1987 Apr 27;82(4A):280–283. [PubMed] [Google Scholar]
  66. Williams A. H., Grüneberg R. N. Ciprofloxacin and co-trimoxazole in urinary tract infection. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):107–110. doi: 10.1093/jac/18.supplement_d.107. [DOI] [PubMed] [Google Scholar]
  67. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Wolfson J. S., Hooper D. C. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Ann Intern Med. 1988 Feb;108(2):238–251. doi: 10.7326/0003-4819-108-2-238. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES